Physician profile
Michael Cameron Ashman
NPI 1518935519
$9,658.33
in general payments reported to CMS, 2019-2025
18 companies · $971 in 2025
The $971 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $232 · 2021: $605 · 2022: $4,968 · 2023: $642 · 2024: $674 · 2025: $971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $4,193.55 | 2019-2025 | Misight Contact Lens |
| Alcon Vision LLC | $2,622.14 | 2019-2025 | Precision7, Total30 |
| Bausch & Lomb Americas INC. | $405.59 | 2022-2025 | Eureka, Biotrue One Day, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $315.62 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $307.14 | 2023-2025 | Acuvue |
| Glaukos Corporation | $265.38 | 2024 | Radius, Istent Infinite Trabecular Micro Bypass System |
| Lkc Technologies, INC. | $253.94 | 2024-2025 | |
| Abbvie INC. | $246.03 | 2022-2025 | Vuity |
| Mallinckrodt Hospital Products INC. | $189.79 | 2023-2024 | Acthar |
| Kala Pharmaceuticals, INC. | $124.93 | 2021 | |
| Aerie Pharmaceuticals, INC. | $124.74 | 2021 | |
| Biotissue Holdings INC. | $121.32 | 2022 | |
| Horizon Therapeutics Plc | $115.20 | 2023 | Tepezza |
| Maculogix, INC. | $108.13 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $97.44 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83.47 | 2022 | |
| Oyster Point Pharma, INC. | $67.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ashman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.